Oral Plus Injectable Meds May Beat Insulin for Type 2 Management
A combination of an oral glucose-lowering medication with an injectable one might be a better option than insulin for people with type 2 diabetes who don’t meet target glucose levels with metformin and a sulfonylurea. Researchers studied 129 such people who had average A1C levels (a reflection of glucose control over time) greater than 7.5 percent. Compared with multiple daily insulin injections, the combination of the oral drug pioglitazone and the injectable exenatide led to a 0.9 percentage point drop in A1C after a year, with three times less hypoglycemia. The combo addresses the two main problems in type 2 diabetes: Exenatide helps the pancreas release more insulin when it’s needed, while pioglitazone reduces insulin resistance.
Source: Diabetes Care, published online Jan. 17, 2017